KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.55

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.

Annoek E C Broers, Cornelis N de Jong, Katerina Bakunina, Mette D Hazenberg, Marinus van Marwijk Kooy, Marco R de Groot, Michel van Gelder, Jürgen Kuball, Bronno van der Holt, Ellen Meijer, Jan J Cornelissen

Blood Adv 6(11) 3378-3385

PMID35143644
PMCIDPMC9198908
DOI10.1182/bloodadvances.2021005847
发表日期2022-02-10
入排依据:The trial is a Phase III randomized controlled trial in oncology (hematological malignancy) with time-to-event endpoints (GRFS, OS, PFS) and reports original results. However, the core intervention is a post-transplant immunosuppressive regimen (cyclophosphamide, cyclosporine, mycophenolic acid) for GVHD prevention, not a primary antineoplastic drug therapy for the malignancy itself. The review criteria require a 'drug-containing intervention' for the malignancy. This study is ambiguous on whether the immunosuppressive drugs are considered the 'drug intervention' in the oncologic sense required for eligibility. Therefore, cannot definitively set is_eligible to true without clarifying this specific criterion.
摘要

摘要

Graft-versus-host disease (GVHD) is the most important complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). We performed a prospective randomized, multicenter, phase 3 trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse-free survival (GRFS) as compared with the combination of CsA and mycophenolic acid (MPA) after nonmyeloablative (NMA) matched related and unrelated peripheral blood alloHSCT. Between October 2013 and June 2018, 160 patients diagnosed with a high-risk hematological malignancy and having a matched related or at least 8 out of 8 HLA-matched unrelated donor were randomized and allocated in a 1:2 ratio to CsA/MPA or PT-Cy/CsA; a total of 151 patients were transplanted (52 vs 99 patients, respectively). The cumulative incidence of grade 2 to 4 acute GVHD at 6 months was 48% in recipients of CsA/MPA vs 30% following PT-Cy/CsA (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.29-0.82; P = .007). The 2-year cumulative incidence of extensive chronic GVHD was 48% vs 16% (HR, 0.36; 95% CI, 0.21-0.64; P < .001). The 1-year estimate of GRFS was 21% (11% to 32%) vs 45% (35% to 55%), P < .001. With a median follow-up of 56.4 months, relapse incidence, progression-free survival, and overall survival were not significantly different between the 2 treatment arms. PT-Cy combined with a short course of CsA after NMA matched alloHSCT significantly improves GRFS due to a significant reduction in severe acute and chronic GVHD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。